10 results about "Antineoplastic chemotherapy" patented technology

The invention discloses an integrated anti-tumor chemotherapeutic drug closed dosing device, and relates to the technical field of chemotherapeutic drug configuration, the integrated anti-tumor chemotherapeutic drug closed dosing device comprises a shell, a plurality of fixing tubes, an isolation assembly and a protection assembly, an inner cavity is formed in the shell, a piston block is slidably arranged in the inner cavity, a pressing rod is fixedly arranged on the outer side of the piston block, an inclined plane is arranged on the outer side of the shell, and the fixing tubes are fixed to the inclined plane; according to the invention, the plurality of needle heads are arranged on the outer side of the shell, the needle heads are communicated with the inner cavity through the fixing tubes, the needle heads are respectively inserted into the sodium chloride solution bag and the medicine bottle, and then the opening and closing of internal channels of the corresponding needle heads are controlled through the isolation assembly; by means of the technical scheme, transferring of a sodium chloride solution, dissolving of medicine powder and transferring of liquid medicine can be achieved under the condition that a needle does not need to be pulled out, so that totally-closed medicine dispensing and transferring of the liquid medicine are achieved, chemotherapy medicine leakage and environmental pollution caused in the medicine preparation process are reduced, and the risk of dangerous medicine occupational exposure of medical staff is reduced.

The invention discloses a lactic acid-responsive nano composite material for antitumor chemotherapy-immunotherapy. The structure of the nano composite material is a nano structure formed by compounding PEGylated viral vaccine protein, lactate oxidase and hollow manganese dioxide loaded with a hypoxia-sensitive chemotherapeutic drug; the nano composite material provided by the invention can simultaneously induce a tumor to release a large amount of antigens, promote an antigen cell presentation process and improve the tolerance of the tumor to immunotherapy, can efficiently activate natural immune response of a tumor part, realizes a tumor inhibition effect, can regulate and control natural immunity of the tumor from multiple aspects, and has a wide application prospect. And safe and efficient anti-tumor chemotherapy-immunotherapy is realized.

To address the shortcomings of existing antitumor chemotherapy drugs, this invention provides a class of pyrazolopyridone derivatives and their preparation method. The compounds are structurally designed and modified using pyrazolopyridone as the parent core, resulting in a class of pyrazolopyridone derivatives (I) with good stability and significant antitumor effects: wherein: R 1 The compound is 4-methoxyphenyl,N-phenylbenzamide. This invention relates to the field of tumor treatment, specifically to a class of novel pyrazolopyridone derivatives with advantages such as structural stability and ease of preparation. These compounds can be used to treat diseases such as tumors and condyloma acuminata.

The application discloses an iron modified ZIF8 nanoparticle encapsulating an antitumor drug and a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method of the nanoparticle comprises the following steps: firstly, preparing a zinc hydroxide loaded antitumor drug, then adding 2-methyl imidazole to obtain a ZIF8 nanoparticle encapsulating the antitumor drug, and finally adding Fe 2+ A methanol solution of a salt is reacted to obtain the iron modified ZIF8 nanoparticle encapsulating the antitumor drug. Through process improvement, the application loads an antitumor chemotherapy drug in the ZIF8 material, so that the ZIF8 material has good acid responsive drug release capacity. Through iron element modification, the nanoparticle is endowed with peroxidase activity, so that the nanoparticle can realize acid and hypoxia responsive chemotherapy and chemical kinetics therapy. The nanoparticle and microorganisms capable of producing lactate oxidase are combined to show super strong non-external field responsive precise tumor treatment capacity.

A class of near-infrared (NIR) II fluorescent dyes, their preparation methods, and their anti-tumor applications belong to the field of fine chemical technology. These dyes have a primary absorption band above 800 nanometers, with fluorescence emission peaks covering both NIR I and II, and exhibit a large Stokes shift (up to 160 nanometers in DMF). These dyes can be used for NIR II optical imaging, avoiding defects such as dye self-absorption, autofluorescence, and fluorescence scattering. When excited by NIR light (808 nm), these dyes generate sufficient reactive oxygen species and heat, enabling them to be used in NIR II fluorescence-guided optical therapy. Furthermore, these dyes can target the specific phospholipid cardiolipin in the inner mitochondrial membrane of cells, interfering with the cardiolipin domain, affecting the activity of cardiolipin-binding proteins, and promoting cell apoptosis. These dyes can be used as novel anti-tumor chemotherapy drugs for cancer treatment.

The present application relates to a kind of isoquinoline alkaloid derivatives for reversing tumor multidrug resistance by inhibiting autophagy and preparation method and application.The derivative can efficiently reverse the multidrug resistance of various solid tumor cells such as gastric cancer, lung cancer and esophageal cancer, the derivative can inhibit the autophagy flow of tumor cells, it is combined with vincristine, mitoxantrone, colchicine, docetaxel and various chemotherapeutic drugs, can efficiently reverse tumor multidrug resistance in vivo and in vitro, this kind of derivative has excellent oral bioavailability and lower toxic side effects, provides a kind of alternative strategy for autophagy inhibitor as antitumor chemosensitizer, can be used as lead compound for the research and development of new drug-resistant tumor reversing agent.

The invention relates to the technical field of organic synthesis, and particularly discloses a 4 '-fluoronucleoside analogue and a synthesis process thereof.The synthesis process comprises the steps that 2'-O-methyladenosine serves as an initial raw material and is subjected to a condensation reaction with benzoyl chloride, and an intermediate 1 is synthesized; carrying out halogenation reaction on the intermediate 1 and iodine, then carrying out elimination reaction on the intermediate 1 and bicyclic amidine, and finally carrying out double-bond addition reaction on the intermediate 1, N-iodosuccinimide and triethylamine trihydrofluoride to synthesize a compound 4; the compound 4 is subjected to an esterification reaction, a nucleophilic substitution reaction and a hydrolysis reaction in sequence, and a target product can be synthesized. The target product disclosed by the invention can be applied to the fields of nucleoside analogs, high stability and antiviral and antitumor chemotherapeutic drugs, and has a wide application prospect.

The invention discloses application of crocetin and a cyclodextrin inclusion compound thereof in assisting in resisting tumors and relieving toxic and side effects in tumor treatment, belongs to the technical field of biological medicines, and particularly relates to application of crocetin or pharmaceutically acceptable salt thereof or combined administration of the cyclodextrin inclusion compound thereof and an anti-tumor chemotherapeutic drug to relieving toxic and side effects in tumor treatment. According to the crocetin cyclodextrin inclusion compound, the water solubility, the stability and the bioavailability of crocetin are remarkably improved. When the clathrate compound is combined with paclitaxel for use, the anti-tumor effect can be enhanced, and nervous system injury, myelosuppression and multi-organ toxicity caused by paclitaxel can be remarkably relieved. Experimental results show that the drug combination scheme shows the dual advantages of synergistic interaction and toxicity reduction in solid tumor models such as prostatic cancer and the like, and has important clinical application prospects.

The present invention relates to a simplified tetrandrine compound that specifically inhibits P-gp and reverses tumor multidrug resistance, as well as a preparation method and application. The simplified tetrandrine compound that specifically inhibits P-gp and reverses tumor multidrug resistance has the following general structure: #imgabs0# The simplified compound can efficiently reverse the multidrug resistance of various solid tumor cells such as gastric cancer, lung cancer, and esophageal cancer. The compound has low cytotoxicity and can specifically inhibit the key efflux pump protein P-gp (P-glycoprotein) that mediates tumor cell multidrug resistance. The simplified compound can be used in combination with various chemotherapy drugs such as vincristine, mitoxantrone, colchicine, and docetaxel to efficiently reverse tumor multidrug resistance both in vivo and in vitro. This type of specific P-gp inhibitor provides an alternative strategy as an anti-tumor chemotherapy sensitizer and can be used as a lead compound for the research and development of new drug-resistant tumor reversal agents.

The present application relates to the preparation of peptides, in particular to a polypeptide component derived from fetal kidney and its preparation method and application, which is used to solve the problems of significant deficiencies in the existing anti-tumor chemotherapy drugs in terms of efficacy, safety, drug resistance and targeting, etc. The polypeptide component derived from fetal kidney and its preparation method, which is extracted and prepared from fetal kidney, shows strong anti-tumor activity in various cancer cell lines, and can effectively inhibit the proliferation of tumor cells; and it shows low toxicity in normal cells, which is a very important characteristic in clinical application, and helps to reduce the side effects on patients during treatment; in addition, the anti-tumor effect of the polypeptide component of the present application is positively correlated with the dose, which provides the possibility for the optimization of the dose in the clinic, and the dose can be adjusted according to the specific condition of the patient to achieve the best efficacy.